Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma - CAPITAL

Study identifier:D361FC00001

ClinicalTrials.gov identifier:NCT05008055

EudraCT identifier:2021-000870-27

CTIS identifier:N/A

Recruitment Complete

Official Title

A Modular Phase II, Open-Label, Multicentre Study to Assess the Efficacy and Safety of Capivasertib in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL)

Medical condition

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Phase

Phase 2

Healthy volunteers

No

Study drug

Capivasertib

Sex

All

Actual Enrollment

30

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 03 Nov 2021
Primary Completion Date: 22 Aug 2023
Estimated Study Completion Date: 31 Dec 2024

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Dec 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

PAREXEL

Inclusion and exclusion criteria